Singapore develops to cure the rare leukemia new medicine

Singapore biotechnology company S*Bio declares that the success develops new medicine of possible treatment rare leukemia and anticipates to will formally turn into the first stage clinical test next year.
S*Bio declares on the 11th and has already successfully developed a kind of code to take orally medicine for the patent of SB1518, will used for cure the marrow increases born nature disease and some types of leukemia.
Marrow's increasing born nature disease is one leukemia rare in kind, the marrow cell organization unusually propagates and results in red corpuscle's being as excessive as blood platelets, and the marrow fiber turns of problem.The new medicine makes the marrow cell unusually bred of signal, stop the cell Be unnatural to multiply greatly and split up behavior.
The experiment of first step suggests that the new medicine is in the tube and lives inside the body, can obtain to repress marrow cell to increase to living and resist the effect of tumor.
S*president of company Sen Doctor of Carl of Bio points out, the marrow increases born nature disease, the sufferer lacks the treatment method of aiming at sex and long term, new medicine once the development is successful, be able to provide a front-line hope for these patients.
This is the S*Bio obtain in the development of anti-cancer medicine in past 12 months the second important breakthrough.The first from Singapore laboratory development of anti-cancer medicine also from S*Bio the company develop and just launched the clinical trial of first stage in this June.
The SB1518 lately anti-cancer medicine anticipates first half year of will start the clinical studies of first stage next year.If the experiment is successful, the medicine will release a market in five years.